bronchiectasi
heterogen
diseas
character
viciou
cycl
airway
infect
inflamm
result
structur
damag
airway
surround
lung
parenchyma
mani
microorgan
associ
bronchiectasi
complic
anatom
abnorm
possibl
caus
structur
diseas
well
divers
polymicrobi
commun
present
airway
patient
bronchiectasi
studi
use
standard
microbiolog
cultur
techniqu
demonstr
presenc
bacteri
fungal
viral
pathogen
lung
bronchiectasi
patient
patient
clinic
stabl
exacerb
diseas
newer
molecular
techniqu
broaden
understand
microbiom
bronchiectasi
patient
pseudomona
aeruginosa
repeatedli
shown
problemat
pathogen
patient
bronchiectasi
associ
wors
prognosi
multipl
epidemiolog
report
shown
approxim
patient
worldwid
bronchiectasi
chronic
infect
p
aeruginosa
sever
antibiot
trial
publish
main
target
therapi
pseudomona
aeruginosa
see
chap
full
review
p
aeruginosa
infect
associ
bronchiectasi
anoth
problemat
group
pathogen
nontubercul
mycobacteria
ntm
common
infect
organ
bronchiectasi
particularli
unit
state
part
asia
ntm
infect
fulli
discuss
chap
chapter
review
role
bacteri
pathogen
p
aeruginosa
impact
fungal
viral
infect
bronchiectasi
patient
see
tabl
clinic
radiograph
featur
bronchiectasi
gener
specif
enough
predict
microbi
pathogen
may
present
age
overal
sever
diseas
evalu
possibl
marker
specif
infect
suffici
specif
pinpoint
infect
organ
one
seri
israel
younger
patient
less
equal
year
bronchiectasi
shown
like
infect
haemophilu
older
patient
pseudomona
enterobacteriacea
seen
larg
patient
cohort
although
patient
sever
diseas
base
sever
score
like
chronic
pseudomona
infect
pathogen
may
present
respons
patient
symptom
radiograph
pattern
diseas
also
suffici
specif
identifi
infect
organ
although
treeinbud
nodular
frequent
thought
diagnost
ntm
infect
recent
studi
shown
treeinbud
find
simpli
repres
endobronchi
inflamm
specif
particular
organ
sputum
color
chart
develop
attempt
correl
degre
sputum
purul
specif
organ
reliabl
predict
cultur
result
henc
imper
sputum
cultur
perform
bronchiectasi
patient
regular
basi
order
target
treatment
assess
prognosi
common
bacteri
organ
report
mani
epidemiolog
seri
haemophilu
influenza
thirti
percent
patient
bronchiectasi
chronic
infect
h
influenza
bronchiectasi
patient
cornerston
therapi
patient
infect
organ
airway
clearanc
variou
modal
includ
mechan
pharmacolog
exercis
patient
infect
h
influenza
exacerb
multipl
oral
antibiot
use
treat
flare
infect
institut
specif
suscept
pattern
patient
toler
dictat
specif
therapi
mainten
inhal
antibiot
gener
recommend
patient
chronic
infect
h
influenza
one
studi
longterm
inhal
gentamicin
includ
patient
chronic
h
influenza
infect
show
benefit
reason
good
toler
studi
use
mainten
aztreonam
inhal
neg
result
chronic
macrolid
therapi
may
appropri
frequent
exacerb
long
appropri
attent
potenti
advers
effect
see
chap
full
review
macrolid
therapi
gramneg
organ
occasion
isol
patient
bronchiectasi
includ
stenotrophomona
maltophilia
klebsiella
pneumonia
moraxella
catarrhali
achromobact
alcaligen
serratia
marcescen
escherichia
coli
routin
cultur
respiratori
secret
necessari
order
track
specif
infect
organ
particular
patient
vital
target
antibiot
therapi
organ
keep
abreast
antibiot
suscept
pattern
may
chang
time
insuffici
data
consensu
use
mainten
antibiot
patient
infect
gramneg
organ
expert
opinion
suggest
therapi
inhal
target
organ
may
use
specif
patient
frequent
exacerb
greater
per
year
requir
system
therapi
andor
patient
bothersom
daili
cough
larg
volum
secret
specif
guidanc
avail
regard
possibl
erad
therapi
gramneg
infect
organ
pseudomona
see
chap
chronic
pseudomona
infect
staphylococcu
aureu
streptococcu
pneumonia
gramposit
organ
frequent
seen
bronchiectasi
patient
us
bronchiectasi
registri
approxim
patient
sputum
cultur
posit
aureu
methicillinsuscept
methicillinresist
strain
pneumonia
treatment
patient
infect
includ
usual
airway
clearanc
modal
target
antibiot
treatment
data
avail
mainten
inhal
antibiot
patient
chronic
infect
gramposit
organ
gramneg
infect
may
role
target
antimicrobi
suppress
therapi
patient
frequent
exacerb
andor
signific
bothersom
daytoday
symptom
chronic
macrolid
therapi
may
role
worrisom
resist
may
develop
particularli
infect
organ
streptococcu
pneumonia
british
thorac
societi
guidelin
suggest
erad
strategi
might
consid
methicillinresist
aureu
infect
organ
first
identifi
although
recommend
base
random
control
trial
littl
data
frequenc
infect
patient
bronchiectasi
us
bronchiectasi
registri
report
small
number
patient
whose
respiratori
cultur
grew
nocardia
decis
proceed
antibiot
treatment
target
nocardia
similar
speci
base
repeatedli
posit
cultur
absenc
anoth
pathogen
might
respons
patient
symptom
unusu
patient
bronchiectasi
cultur
normal
oropharyng
flora
respiratori
secret
extent
may
repres
limit
routin
cultur
techniqu
identifi
infect
organ
patient
bronchiectasi
addit
difficulti
patient
produc
suffici
sputum
laboratori
process
one
small
studi
greek
patient
bronchiectasi
sought
identifi
whether
mycoplasma
pneumonia
chlamydia
pneumonia
respiratori
syncyti
viru
rsv
might
present
bronchoalveolar
lavag
specimen
find
essenti
neg
new
research
understand
respiratori
microbiom
see
may
help
understand
organ
may
play
role
symptom
associ
bronchiectasi
aspergillu
candida
commonli
found
respiratori
secret
patient
bronchiectasi
approxim
patient
us
registri
cultur
posit
aspergillu
cohort
patient
report
spain
show
small
number
patient
persist
cultur
posit
aspergillu
candida
difficult
determin
organ
play
role
infecti
symptom
simpli
bystand
organ
patient
primari
pathogen
treatment
aim
aspergillu
consid
patient
persist
posit
cultur
without
anoth
organ
might
culpabl
candida
rare
requir
treatment
usual
oral
contamin
import
identifi
patient
syndrom
allerg
bronchopulmonari
aspergillosi
caus
bronchiectasi
immunolog
disord
distinct
secondari
infect
due
aspergillu
role
viral
infect
bronchiectasi
unclear
littl
data
avail
whether
patient
may
chronic
infect
virus
role
virus
trigger
exacerb
cohort
chines
adult
bronchiectasi
respiratori
virus
found
frequent
molecular
test
nasopharyng
swab
sputum
sampl
patient
exacerb
symptom
compar
stabl
state
commonli
identifi
virus
coronaviru
rhinoviru
influenza
b
rsv
also
found
bronchoalveolar
lavag
bal
specimen
patient
exacerb
bronchiectasi
symptom
season
variabl
exacerb
bronchiectasi
also
postul
due
viral
exposur
patient
bronchiectasi
exacerb
may
benefit
screen
viral
infect
particularli
influenza
season
yearli
vaccin
influenza
also
recommend
patient
bronchiectasi
microorgan
pseudomona
signific
impact
patient
bronchiectasi
understand
wide
spectrum
bacteria
infect
patient
includ
ntm
grow
know
less
impact
fungal
viral
pathogen
bronchiectat
lung
impact
coinfect
multipl
organ
also
poorli
understood
especi
regard
organ
target
specif
antibiot
treatment
current
clinic
avail
microbiolog
techniqu
provid
full
understand
microbiolog
divers
within
lung
bronchiectasi
patient
may
learn
ongo
research
lung
microbiom
well
impact
antimicrobi
therapi
balanc
organ
within
microbiom
present
time
imper
clinician
care
monitor
microbiolog
result
patient
bronchiectasi
order
provid
optim
judici
antibiot
treatment
well
help
assess
prognosi
individu
patient
frequenc
monitor
type
pathogen
routin
bacteri
mycobacteri
viral
fungal
clearli
spell
exist
guidelin
sputum
sampl
handl
collect
process
also
vari
region
region
laboratori
laboratori
patient
establish
bronchiectasi
care
microbiolog
surveil
stabl
exacerb
state
need
clinician
need
awar
local
microbiolog
data
need
track
result
individu
patient
close
interact
local
microbiolog
laboratori
may
also
improv
antibiot
stewardship
patient
bronchiectasi
clinician
strongli
consid
establish
protocol
obtain
sputum
cultur
regular
interv
bronchiectasi
patient
base
upon
local
infect
pattern
overal
experi
patient
clear
routin
bacteri
mycobacteri
surveil
need
routin
fungal
cultur
may
may
valu
viral
cultur
probabl
worthwhil
time
exacerb
research
need
area
better
standard
role
microbiolog
cultur
microbiom
result
improv
clinic
outcom
patient
bronchiectasi
